Zosuquidar (LY335979) 3HCl: Benchmark P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent and specific inhibitor of P-glycoprotein (P-gp), an ATP-dependent efflux pump implicated in cancer multidrug resistance (MDR) (Sun et al., 2025). At 0.1 μM, it fully restores sensitivity to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp–overexpressing cell lines (ref). In murine and xenograft models, Zosuquidar enhances chemotherapeutic efficacy without altering drug pharmacokinetics (Sun et al., 2025). Clinical trials have confirmed effective P-gp inhibition with minimal toxicity (ref). APExBIO provides Zosuquidar (A3956) in a stable, DMSO-soluble trihydrochloride form for research use only (product page).

Biological Rationale

P-glycoprotein (P-gp; also known as MDR1 or ABCB1) functions as an ATP-binding cassette (ABC) transporter. It is highly expressed in the brain, liver, intestine, kidney, and many tumor cells (Sun et al., 2025). P-gp mediates efflux of a wide range of xenobiotics and chemotherapeutics, reducing intracellular drug concentration. This activity underlies multidrug resistance (MDR) in cancers such as acute myeloid leukemia (AML), non-Hodgkin's lymphoma, and various solid tumors. Overexpression of P-gp is a key mechanism of chemotherapy failure. Inhibiting P-gp can restore drug accumulation and cytotoxicity in resistant cancer cells. Zosuquidar (LY335979) 3HCl is designed to target this mechanism specifically, with high selectivity and potency for P-gp over related transporters (ref).

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar competitively inhibits P-gp by blocking the substrate binding site. It prevents the efflux of structurally diverse chemotherapeutic agents, including vinblastine, doxorubicin, and paclitaxel. Zosuquidar does not inhibit other major ABC transporters at standard research concentrations (ref). Inhibition is observed at sub-micromolar levels (0.1–1 μM), fully reversing drug resistance in vitro. Zosuquidar is effective in P-gp–overexpressing leukemia and solid tumor models. The compound does not significantly alter the pharmacokinetics of co-administered chemotherapeutics in vivo, indicating selective P-gp modulation (Sun et al., 2025).

Evidence & Benchmarks

• At 0.1 μM, Zosuquidar completely reverses vinblastine resistance in P-gp–overexpressing leukemia cell lines (Sun et al., 2025).
• Zosuquidar increases intracellular accumulation of doxorubicin and restores cytotoxicity in resistant solid tumor cells (ref).
• In murine leukemia and human lung carcinoma xenograft models, Zosuquidar enhances the antitumor effects of paclitaxel and etoposide without altering systemic exposure or clearance (Sun et al., 2025).
• Phase I/II trials in non-Hodgkin's lymphoma and advanced solid tumors demonstrate that Zosuquidar, in combination with CHOP or vinorelbine regimens, is well tolerated and achieves effective P-gp inhibition (ref).
• Zosuquidar does not significantly inhibit hepatic cytochrome P450s or other major efflux transporters at research concentrations (ref).

This article extends the practical workflows and troubleshooting focus of "Zosuquidar: P-gp Inhibitor Optimizing Multidrug Resistance Research" by providing new clinical and pharmacokinetic benchmarks. It also updates the strategic context presented in "Strategic Innovation in Overcoming Multidrug Resistance" with recent evidence on in vivo selectivity and tolerability.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is used to:

• Overcome P-glycoprotein–mediated multidrug resistance in cancer research models.
• Restore chemosensitivity in P-gp–overexpressing AML, non-Hodgkin's lymphoma, and solid tumors.
• Benchmark P-gp inhibition assays and drug efflux studies.
• Evaluate MDR-reversal strategies in translational and preclinical settings.

Limits include lack of efficacy in MDR driven by non–P-gp mechanisms (e.g., MRP2, BCRP), variable effects in primary tumor samples, and research-only status (not for human therapy). Clinical use requires further safety and efficacy validation.

Common Pitfalls or Misconceptions

• Zosuquidar is not a pan-ABC transporter inhibitor: It is highly selective for P-gp and does not inhibit MRP2 or BCRP at standard concentrations.
• Not effective in P-gp–negative MDR: Tumors with efflux driven by other mechanisms will not respond.
• Research use only: Zosuquidar (LY335979) 3HCl from APExBIO is not approved for diagnostic or therapeutic use in humans.
• Stability limitations: Solutions in DMSO should not be stored long-term; compound is stable at -20°C as a solid.
• No effect on upstream resistance pathways: Zosuquidar does not modulate PI3K/Akt/mTOR or apoptosis directly.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl is supplied as a trihydrochloride salt, molecular weight 527.6 g/mol, formula C₃₂H₃₁F₂N₃O₂. It is soluble in DMSO and should be stored at -20°C. For in vitro MDR reversal, use 0.1–1 μM; for in vivo studies, refer to published protocols for dosing and administration route. Do not store diluted solutions for extended periods. APExBIO (SKU A3956) provides quality assurance and batch consistency (APExBIO product page). For troubleshooting and advanced workflows, see the scenario guide in "Mastering Multidrug Resistance: Scenario Strategies with Zosuquidar"; this article offers an updated framework for experimental reproducibility and assay validation.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl remains a gold-standard reagent for reversing P-gp–mediated multidrug resistance in cancer models. Its selectivity, minimal off-target effects, and robust in vitro and in vivo performance make it an essential tool for MDR research. Ongoing work aims to extend its utility to combinatorial regimens and to refine assay protocols for translational studies. For consistent results, source Zosuquidar directly from APExBIO and follow validated storage and usage guidelines (Zosuquidar (LY335979) 3HCl).